Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...

Altimmune is redefining success in both obesity and MASH to position Pemvidutide in blue ocean categories. Read why I rate ...

Shares in Novo Nordisk have fallen by more than a quarter after the Ozempic maker revealed a set of underwhelming results in ...

The company plans to leverage research and development incentives from the Australian Government to offset the trial costs.

Novo Nordisk shares on the NYSE rose over 5% in premarket trading Monday, reversing some losses from Friday’s plunge that ...

Novo Nordisk plans a new trial for its experimental drug, CagriSema, in 2025 after recent trials failed to meet weight-loss expectations. Despite aiding patients to reduce weight by 22.7%, it fell ...

(Figure S2); XPS quantitative analysis of commercial GO materials (Table S1); flowchart illustrating the experimental procedure of the acid–solvent method (Figure S3); FTIR spectra before and after ...

UBS analyst Trung Huynh says Novo Nordisk’s CagriSema Phase 3 topline obesity data “underwhelmed,” a positive read-through to Eli Lilly and Amgen . CagriSema achieved an ave ...

This whitepaper explores how AAV titration and anti-AAV antibody ELISA kits streamline AAV-based gene therapy research, ...

I was about 23 and was still finding my feet socially in London. I’d always really been a champagne girl at heart but ...

Hims & Hers Health, Inc. has shown significant improvement in key unit economics, positioning it among top-tier SaaS ...